3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
CNS
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Bronchogenic
1
Interventions
Filgrastim
15
Carboplatin
10
Ifosfamide
9
Doxorubicin
9
Cyclophosphamide
9
Peripheral Blood Stem Cell Transplantation
7
pembrolizumab
6
Radiotherapy
6
Gemcitabine
6
Temozolomide
5
Etoposide
5
Cisplatin
5
Paclitaxel
4
Docetaxel
4
Amifostine
4
aldesleukin
3
aflibercept
3
Trastuzumab
3
Specimen Handling
3
Radiosurgery
3
Psychiatric Rehabilitation
3
Magnetic Resonance Spectroscopy
3
Biopsy
3
tislelizumab
2
sodium thiosulfate
2
selinexor
2
pazopanib
2
palbociclib
2
etoposide phosphate
2
eribulin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Interleukin-15
×
Gynecologic
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled